The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

B cells are central to the adaptive immune response, not only through the production of antibodies but also via their crucial roles in antigen presentation and cytokine secretion. Research over recent ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, immunotherapy is referred to treating cancer. As tumors progress, they secrete ...

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy has transformed cancer treatment by activating T-cells—a type of immune ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...